$Harrow (HROW.US)$Second Quarter 2024 and Recent Selected Highlights: ● Record revenues of $48.9 million ● GAAP net loss of $(6.5) million ● Adjusted EBITDA of $8.8 million ● Cash and cash equivalents of $71.0 million as of June 30, 2024 ● IHEEZO® customer unit demand volume increased by 98% from the first quarter of 2024 ● IHEEZO supply agreements total 24 agreements to date in 2024, including a recent win with the largest and highest volume U.S. retina practice group ● VEVYE® total prescriptions increased by 212% from the first quarter of 2024 ● Anterior Segment revenues up over 40% from the first quarter of 2024 ● Record quarterly revenues from Harrow’s ImprimisRx subsidiary
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more